UGT79B8 Antibody

What is UGT8 and why is it an important research target?

UGT8 (UDP glycosyltransferase 8) belongs to the UDP-glycosyltransferase family and catalyzes the transfer of galactose to ceramide, which is a key enzymatic step in the biosynthesis of galactocerebrosides. These are abundant sphingolipids found in the myelin membrane of both central and peripheral nervous systems. Additionally, UGT8 has been identified as a key player in basal-like breast cancer (BLBC) progression through activating the sulfatide–αVβ5 axis . The protein has a calculated molecular weight of approximately 61 kDa and has been studied extensively in human, mouse, and rat models . The significance of UGT8 in both neural development and cancer progression makes it an important target for both basic and translational research.

What are the most common applications for UGT8 antibodies in research?

UGT8 antibodies have been validated for multiple research applications, with the most common being:

• Western Blot (WB): Used for detecting UGT8 protein in tissue or cell lysates, typically at dilutions of 1:500-1:2000

• Immunohistochemistry (IHC): Used for visualizing UGT8 expression in tissue sections, at dilutions of 1:20-1:200 or 1:50-1:400 depending on the specific antibody

• Immunoprecipitation (IP): Used for isolating UGT8 protein complexes from cell lysates

• Immunofluorescence/Immunocytochemistry (IF/ICC): Used for cellular localization studies of UGT8

These applications have been validated with tissues and cell lines from human, mouse, and rat origins, making UGT8 antibodies versatile tools for comparative species studies .

What tissues and cell types typically express UGT8?

Based on the experimental data from antibody validation studies, UGT8 expression has been positively detected in:

• Brain tissue: UGT8 has been consistently detected in rat brain tissue by Western blot and immunoprecipitation methods

• Human brain tissue: Detected through immunohistochemistry

• Breast cancer cells: Particularly elevated expression in basal-like breast cancer (BLBC) cell lines compared to luminal breast cancer cell lines

• Human breast cancer tissue: Detected through immunohistochemistry

Notably, research has shown that UGT8 mRNA and protein expression are significantly higher in BLBC cells than in luminal cells, and this differential expression pattern may have clinical implications for breast cancer research and potential therapeutic strategies .

How does UGT8 contribute to basal-like breast cancer progression?

UGT8 has been identified as a significant contributor to basal-like breast cancer (BLBC) progression through several mechanistic pathways:

• Metabolite production: UGT8 is required for increased galactosylceramide (GalCer) and sulfatide production in breast cancer cells. Both knockdown and overexpression experiments have demonstrated that UGT8 directly regulates the levels of these metabolites .

• Signaling pathway activation: UGT8 primarily functions through the αVβ5-mediated signaling pathway. Studies have shown that manipulating UGT8 expression levels significantly affects αVβ5 clustering, with knockdown causing a decrease and overexpression leading to an increase in αVβ5 clustering .

• Selective interaction: Interestingly, UGT8 appears to selectively affect αVβ5 clustering with only minimal effects on αVβ3 clustering, indicating a specific mechanistic pathway .

These findings suggest that UGT8 promotes BLBC progression specifically through activating the sulfatide–αVβ5 axis, making it a potential therapeutic target for this aggressive breast cancer subtype .

What are the considerations for antibody specificity when studying UGT8 in different experimental contexts?

When selecting and validating UGT8 antibodies for specific experimental contexts, researchers should consider:

• Cross-reactivity profile: While commercial UGT8 antibodies generally show reactivity with human, mouse, and rat samples, the degree of cross-reactivity may vary between species. Validation experiments should be performed when working with less common species .

• Isoform specificity: The UGT8 gene has alternatively spliced transcript variants, which may produce protein isoforms with different properties. Antibodies may have varying affinities for these isoforms, potentially leading to inconsistent results across experimental systems .

• Epitope accessibility: The immunogen used for antibody production is an important consideration. For example, the Boster Bio antibody (A07967-2) uses an E.coli-derived human UGT8 recombinant protein covering positions T40-L399, which may affect epitope accessibility in certain applications where protein folding or post-translational modifications alter epitope exposure .

• Validation methods: Thorough validation using known positive and negative controls is essential for confirming antibody specificity. This should include multiple techniques such as Western blot, IHC, and other relevant applications for your research question .

What methodological approaches can detect UGT8 activity versus merely measuring expression levels?

Distinguishing between UGT8 expression and enzymatic activity requires specific methodological approaches:

• Enzymatic activity assays: UGT8 activity can be measured by quantifying the conversion of ceramide to galactosylceramide. This has been demonstrated in studies comparing BLBC cells with luminal cells, showing that UGT8 activity correlates with protein expression levels but provides a functional measurement rather than just presence .

• Metabolite quantification: Measuring downstream metabolites (GalCer and sulfatide) using techniques such as immunoblotting or mass spectrometry provides indirect evidence of UGT8 activity in experimental systems .

• Functional knockdown/overexpression studies: Creating stable transfectants with empty vector or knockdown of UGT8 expression can help assess the functional consequences of UGT8 activity. Similarly, stable clones with empty vector or UGT8 expression provide models for understanding activity in different cellular contexts .

• Immunostaining-confocal analysis: This approach can be used to visualize both UGT8 expression and its metabolic products, providing spatial information about enzyme activity within cells or tissues .

What are the optimal sample preparation techniques for UGT8 antibody applications?

The effectiveness of UGT8 antibody applications depends significantly on proper sample preparation:

For all applications, it's important to include proper controls and to titrate the antibody concentration to achieve optimal signal-to-noise ratio in your specific experimental system .

How can researchers troubleshoot non-specific binding when using UGT8 antibodies?

Non-specific binding is a common issue when working with antibodies. For UGT8 antibodies specifically, consider these troubleshooting approaches:

• Blocking optimization: When excessive background is observed, try different blocking reagents (BSA, milk, normal serum) at various concentrations and incubation times.

• Antibody dilution: Test a range of dilutions beyond the recommended range. For Western blot, try extended ranges from 1:250 to 1:5000 to find the optimal signal-to-noise ratio for your specific sample .

• Cross-reactivity assessment: If unexpected bands appear in Western blot or non-specific staining occurs in IHC/IF, consider:

  • Using UGT8 knockout/knockdown samples as negative controls

  • Peptide competition assays with the immunizing peptide to confirm specificity

  • Testing the antibody on a panel of tissues known to express or not express UGT8

• Sample preparation modifications: For membrane proteins like UGT8, detergent composition and concentration in lysis buffers can significantly affect epitope accessibility and background. Experiment with different detergent types and concentrations .

What are the recommended controls for validating UGT8 antibody specificity in different applications?

Proper controls are essential for validating antibody specificity:

• Positive controls:

  • Rat brain tissue for Western blot and immunoprecipitation

  • Human brain tissue and human breast cancer tissue for immunohistochemistry

  • BLBC cell lines (e.g., MDA-MB231, SUM159) which have been shown to express high levels of UGT8

• Negative controls:

  • Primary antibody omission control

  • Isotype control using matched concentration of non-specific IgG

  • UGT8 knockdown/knockout samples (as demonstrated in published research)

• Specificity controls:

  • Peptide competition/blocking experiments using the specific immunogen

  • Multiple antibodies targeting different epitopes of UGT8 to confirm consistent patterns

• Functional validation:

  • Correlation of staining/signal intensity with UGT8 activity assays

  • Demonstration of expected changes in downstream metabolites (GalCer and sulfatide) upon manipulation of UGT8 expression

How can researchers quantitatively analyze UGT8 expression data from different experimental platforms?

Quantitative analysis of UGT8 expression requires platform-specific approaches:

• Western blot quantification:

  • Use appropriate housekeeping genes for normalization (β-actin, GAPDH)

  • Employ densitometry software (ImageJ, Image Lab, etc.) for quantification

  • Present results as fold change relative to control conditions

• IHC/IF quantification:

  • For IHC: Use established scoring systems such as H-score or Allred score

  • For IF: Measure mean fluorescence intensity using image analysis software

  • Consider automated image analysis methods for unbiased quantification

• Multi-omics data integration:

  • Correlate protein expression data with mRNA expression from RNA-seq or qPCR

  • Compare UGT8 expression with relevant metabolomics data (GalCer, sulfatide levels)

  • Use publicly available datasets (like those mentioned in search result : GSE12777, GSE10890, E-TABM-157, and E-MTAB-181) for comparative analysis

• Statistical considerations:

  • Apply appropriate statistical tests based on data distribution

  • Account for biological and technical replicates in experimental design

  • Consider power analysis to determine adequate sample sizes for detecting biologically meaningful differences in UGT8 expression